Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Eisai Deal A Milestone On HUYA’s Evolving Road

This article was originally published in PharmAsia News

Executive Summary

A recent exclusive license agreement with Eisai for a cancer compound discovered by a Chinese company builds on HUYA Bioscience’s position as a leader in accelerating the global development of novel biopharmaceutical products originating in China, and the firm says it will continue to pursue further deals based on its database of 14,000 China-sourced compounds across multiple therapeutic areas.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register